Latest News

Liver Disease: Efruxifermin Showed 39% Cirrhosis Reversal in MASH Patients in the Phase 2b SYMMETRY Study
Written by: Radcliffe CKM
Liver Disease: Efruxifermin Showed 39% Cirrhosis Reversal in MASH Patients in the Phase 2b SYMMETRY Study
Serum Uric Acid as an Independent Predictor of Non-Alcoholic Fatty Liver Disease in Non-Obese Young Adults
Written by: Radcliffe CKM
Serum Uric Acid as an Independent Predictor of Non-Alcoholic Fatty Liver Disease in Non-Obese Young…
Late-Breaking Trail and Featured Clinical Research Presentations Revealed for ACC Scientific Sessions 2025
Written by: ACC 2025
Late-Breaking Trial and Featured Clinical Research Presentations Revealed for ACC Scientific Sessions…
BPROAD: Promising Results for Intensive Blood Pressure Control in Type 2 Diabetes Patients
Written by: Radcliffe CKM
BPROAD: Promising Results for Intensive Blood Pressure Control in Type 2 Diabetes Patients
AHA 24: PALISADE Trial Shows Promise for Patients with Familial Chylomicronemia Syndrome
Written by: Radcliffe Cardiology
AHA 24: PALISADE Trial Shows Promise for Patients with Familial Chylomicronemia Syndrome
ATTRibute-CM Open-Label Extension (OLE) Study: Sustained Benefits of Acoramidis in ATTR-CM
Written by: Radcliffe Cardiology
ATTRibute-CM Open-Label Extension (OLE) Study: Sustained Benefits of Acoramidis in ATTR-CM
Novel Agent Data for Obesity Released at ADA 2024 Scientific Sessions Show Benefits for Glycaemic and Blood Pressure Control
Written by: Radcliffe Cardiology
Novel Agent Data for Obesity Released at ADA 2024 Scientific Sessions Show Benefits for Glycaemic and…
FLOW Trial Analysis: Deep Dive into the SGLT2-GLP-1 Combination Therapy
Written by: Radcliffe Cardiology
FLOW Trial Analysis: Deep Dive into the SGLT2-GLP-1 Combination Therapy
SURMOUNT-OSA: Tirzepatide Significantly Improves Sleep Apnea and Cardiometabolic Risk Factors
Written by: Radcliffe Cardiology
SURMOUNT-OSA: Tirzepatide Significantly Improves Sleep Apnea and Cardiometabolic Risk Factors
Timing of Cardio-Kidney Protection with SGLT2 Inhibitors
Written by: Radcliffe Cardiology
Timing of Cardio-Kidney Protection with SGLT2 Inhibitors

External news

Written by: Cardiac Vascular News
Nyra Medical Announces First Patient Enrollment in ENHANCE Early Feasibility Study, Advancing Next Generation Mitral Valve Repair Platform
Written by: Cardiovascular Business
Why cardiology leaders should be careful about the quality metrics they focus on
Written by: Cardiovascular Business
ACC takes on DOAC use with new scientific statement
Written by: Cardiovascular Business
FDA approves labeling change for Gore EVAR devices
Written by: Cardiac Vascular News
Catalyst MedTech Announces Channel Partnership with APQ Health to Expand Access to Advanced Cardiac CT Analysis
Written by: Cardiovascular Business
Exploring key breakthroughs in VT ablation
Written by: Medscape
Lipids Management
Written by: Cardiac Vascular News
Larkin Community Hospital Palm Springs Recognized by American Heart Association for Excellence in Stroke Care
Written by: Cardiac Vascular News
First Patient Enrolled in Penumbra’s FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke
Written by: Cardiac Vascular News
Cleerly to Debut Customizable Full Text Reports and Present New AI-QCT Research at SCCT2026